Skip to content

The Impact of Hypothermia Therapy on Gut Microbiota in Post-Cardiopulmonary Resuscitation Patients

The Impact of Hypothermia Therapy on Gut Microbiota in Post-Cardiopulmonary Resuscitation Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500096171
Enrollment
Unknown
Registered
2025-01-20
Start date
2025-01-24
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

case series:none

Sponsors

Qilu Hospital of Shandong University (Qingdao)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Aged 18 years or older, regardless of gender; Successfully resuscitated after cardiopulmonary resuscitation (including chest compressions, defibrillation, etc.) and in the acute recovery phase (usually within 24 hours); Willing to participate in the study and sign the informed consent form; Meeting the indications for hypothermia therapy; Clinically stable at the time of entering the study and able to tolerate the intervention measures of the study; Able to undergo gut microbiota sampling (e.g., stool samples) and without severe gastrointestinal bleeding or contraindications for surgery.

Exclusion criteria

Exclusion criteria: Severe comorbidities or end-stage diseases: such as end-stage liver disease, renal failure, terminal cancer, etc., with a short life expectancy or those unable to undergo effective treatment; Pregnant or breastfeeding women; Severe cardiovascular and cerebrovascular diseases: such as cardiogenic shock, severe arrhythmias, cerebrovascular accidents, etc., that prevent the patient from tolerating hypothermia therapy after cardiopulmonary resuscitation; Gut dysfunction: including severe acute intestinal injury, intestinal obstruction, or other diseases affecting normal bowel function; Immunosuppressive states: such as patients on immunosuppressive drugs or those with obvious immune dysfunction (e.g., HIV infection, organ transplant recipients, etc.); Failure to meet the indications for hypothermia therapy; Patients or their family members who have not signed the informed consent form or who refuse to participate in the study.

Design outcomes

Primary

MeasureTime frame
Changes in the composition of intestinal flora;

Secondary

MeasureTime frame
Heart rate variability;intestinal barrier function;Inflammatory response marker;GCS score;ICU Mortality Rate ;28-Day Mortality Rate;SOFA Score and APACHE II Score;

Countries

China

Contacts

Public ContactZhiyang Wu

Qilu Hospital of Shandong University (Qingdao)

wzy838983646@126.com+86 185 6181 2387

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026